Aldeyra Therapeutics is a biotechnology company focused on discovering and developing therapies designed to treat immune-mediated diseases. Co.'s primary product candidate, reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. Co. has additional product candidates in development for autoimmune diseases and other immune-mediated disease, as well as for proliferative vitreoretinopathy (PVR) and other retinal diseases. Co. has rights to ADX-2191, a vitreous-compatible methotrexate formulation for intraocular injection, for the prevention of PVR, a retinal disease, and primary vitreoretinal lymphoma, a rare cancer. We show 41 historical shares outstanding datapoints in our coverage of ALDX's shares outstanding history.
Understanding the changing numbers of ALDX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ALDX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ALDX by allowing them to research ALDX shares outstanding history
as well as any other stock in our coverage universe. |
Free ALDX Email Alerts:
Video: Shares Outstanding Importance
